Product Description
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Melanoma|Head and Neck Cancer|Squamous Cell Carcinoma|Colorectal Cancer|Prostate Cancer|Glioblastoma
Phase 1: Oncology Solid Tumor Unspecified|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| I205 | P2 |
Completed |
Prostate Cancer |
2015-01-13 |
|
| PX-866-007 | P2 |
Terminated |
Melanoma |
2014-12-01 |
51% |
| I204 | P2 |
Completed |
Glioblastoma |
2014-10-29 |
|
| PX-866-002 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer |
2013-12-01 |
51% |